Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX)
Health Care · Pharmaceuticals · US
$37.52
-1.65% today · +348.8% 1Y
Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.25B and employs 136 people.
Over the last twelve months the share price has gained 348.8%, trading between 8.46 and 41.14.
Tweenvest scores Amylyx Pharmaceuticals, Inc. across four factors: quality 37/100. Its strongest factor is quality.
AMLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.25B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.43
- Dividend yield
- —
- Beta (5Y)
- -0.20
- 52-week high
- $41.14
- 52-week low
- $8.46
- Avg volume (3M)
- —
- Shares outstanding
- 111.42M
- Employees
- 136
- Next earnings
- —
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
- ISIN
- US03237H1014
- Founded
- 2013
- Listed since
- Jan 7, 2022
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,251.95 | +0.40% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.12 | +0.03% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $155.00 | +2.88% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.42 | +1.61% |
Figures last refreshed Aug 18, 2026.